Sandbox:Preeti: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 7: | Line 7: | ||
! colspan="2" rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease | ! colspan="2" rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease | ||
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology | ! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology | ||
! colspan="10" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical manifestations | ! colspan="10" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical manifestations | ||
! colspan="8" align="center" style="background:#4479BA; color: #FFFFFF;" + |Paraclinical findings | ! colspan="8" align="center" style="background:#4479BA; color: #FFFFFF;" + |Paraclinical findings | ||
Line 26: | Line 25: | ||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Other | ! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Other | ||
|- | |- | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Constitutional symptoms | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Constitutional symptoms | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Rash | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Rash | ||
Line 40: | Line 37: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt | ||
|- | |- | ||
! colspan=" | ! colspan="24" align="left" style="background:#4479BA; color: #FFFFFF;" + |HL | ||
|- | |- | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + | | ! align="center" style="background:#4479BA; color: #FFFFFF;" + | | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Hodgkin's Lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Hodgkin's Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 68: | Line 63: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! colspan=" | ! colspan="24" align="left" style="background:#4479BA; color: #FFFFFF;" + |NHL | ||
|- | |- | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |B Cell Lymphoma | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |B Cell Lymphoma | ||
Line 74: | Line 69: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Precursor B-cell Lymphoma | * Precursor B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 103: | Line 96: | ||
* Reciprocal translocation t(14;18)(q32;q21) | * Reciprocal translocation t(14;18)(q32;q21) | ||
* Overexpression of ''BCL2'' | * Overexpression of ''BCL2'' | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Second most common subtype of NHL | * Second most common subtype of NHL | ||
Line 147: | Line 138: | ||
* [[CD5 (protein)|CD5]] positive antigen in pregerminal center of B-cell | * [[CD5 (protein)|CD5]] positive antigen in pregerminal center of B-cell | ||
* [[Chromosomal translocation]] at '''t(11:14)''' | * [[Chromosomal translocation]] at '''t(11:14)''' | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 192: | Line 181: | ||
* Mutation of ''BCL6'', ''MYC'', ''[[PAX5]]'', ''[[PIM1]]'', ''[[RhoH]]'' /''TTFn'', ''[[TP53]]'' genes | * Mutation of ''BCL6'', ''MYC'', ''[[PAX5]]'', ''[[PIM1]]'', ''[[RhoH]]'' /''TTFn'', ''[[TP53]]'' genes | ||
* Translocations involving ''c-MYC'', ''BCL6'', and ''IgH'' gene. | * Translocations involving ''c-MYC'', ''BCL6'', and ''IgH'' gene. | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 232: | Line 219: | ||
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease | ! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Demography | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Demography | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |History | ||
Line 263: | Line 248: | ||
** t(2;8) | ** t(2;8) | ||
** t(8;22) | ** t(8;22) | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 308: | Line 291: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 336: | Line 317: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 366: | Line 345: | ||
** Deletion 7q21-32 | ** Deletion 7q21-32 | ||
** Translocations of the CDK6 gene located on 7q21 | ** Translocations of the CDK6 gene located on 7q21 | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 400: | Line 377: | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
* Stimulation of antigen receptor by autoantigen and co-stimulatory molecule CD40 | * Stimulation of antigen receptor by autoantigen and co-stimulatory molecule CD40 | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 436: | Line 411: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 466: | Line 439: | ||
** The ''MEK-ERK'' cascade | ** The ''MEK-ERK'' cascade | ||
** The ''Phosphatidylinositol 3 kinase (PI3K)-AKT'' cascade | ** The ''Phosphatidylinositol 3 kinase (PI3K)-AKT'' cascade | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 521: | Line 492: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Precursor T-cell Lymphomas | * Precursor T-cell Lymphomas | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 547: | Line 516: | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Adult T cell leukemia/lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Adult T cell leukemia/lymphoma | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 573: | Line 540: | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Anaplastic large cell lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Anaplastic large cell lymphoma | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 602: | Line 567: | ||
* The [[tumor]] [[Cell (biology)|cells]] originate from [[memory T cells]] or [[skin]] homing [[CD4+ T cells]] expressing [[cutaneous]] [[lymphocyte]] [[antigen]] (CLA) and [[chemokine]] [[receptors]] [[CCR4]]<nowiki/>and CCR7. | * The [[tumor]] [[Cell (biology)|cells]] originate from [[memory T cells]] or [[skin]] homing [[CD4+ T cells]] expressing [[cutaneous]] [[lymphocyte]] [[antigen]] (CLA) and [[chemokine]] [[receptors]] [[CCR4]]<nowiki/>and CCR7. | ||
* It is understood that cutaneous t cell lymphoma (maycosis fungoides, Sezary sydrome ) is the result of malignant T cell that derived from a mature CD41 CD45RO1 memory T cells. | * It is understood that cutaneous t cell lymphoma (maycosis fungoides, Sezary sydrome ) is the result of malignant T cell that derived from a mature CD41 CD45RO1 memory T cells. | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 639: | Line 602: | ||
! rowspan="6" align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma | ! rowspan="6" align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma | ||
! align="center" style="background:#DCDCDC;" + |Subcutaneous panniculitis-like T-cell lymphoma | ! align="center" style="background:#DCDCDC;" + |Subcutaneous panniculitis-like T-cell lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 665: | Line 626: | ||
| | | | ||
! align="center" style="background:#DCDCDC;" + |Hepatosplenic gamma-delta T-cell lymphoma | ! align="center" style="background:#DCDCDC;" + |Hepatosplenic gamma-delta T-cell lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 691: | Line 650: | ||
| | | | ||
! align="center" style="background:#DCDCDC;" + |Enteropathy-type intestinal T-cell lymphoma | ! align="center" style="background:#DCDCDC;" + |Enteropathy-type intestinal T-cell lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 717: | Line 674: | ||
| | | | ||
! align="center" style="background:#DCDCDC;" + |Extranodal T-cell lymphoma, nasal type | ! align="center" style="background:#DCDCDC;" + |Extranodal T-cell lymphoma, nasal type | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 743: | Line 698: | ||
| | | | ||
! align="center" style="background:#DCDCDC;" + |Angioimmunoblastic T-cell lymphoma | ! align="center" style="background:#DCDCDC;" + |Angioimmunoblastic T-cell lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 769: | Line 722: | ||
| | | | ||
! align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma, unspecified | ! align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma, unspecified | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | |
Revision as of 19:14, 7 January 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]
Category | Disease | Etiology | Clinical manifestations | Paraclinical findings | Gold standard | Associated findings | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lab findings | |||||||||||||||||||||||
Demography | History | Symptoms | Signs | CBC | PBS | PT/PTT | Immunochemistry | Histopathology | Other | ||||||||||||||
Constitutional symptoms | Rash | Abdominal pain | Diarrhea | V/S | Mass | Hepatosplenomegaly | Other | WBC | Hb | Plt | |||||||||||||
HL | |||||||||||||||||||||||
Hodgkin's Lymphoma | |||||||||||||||||||||||
NHL | |||||||||||||||||||||||
B Cell Lymphoma | Precursor B-cell lymphoblastic leukemia/lymphoma |
|
|||||||||||||||||||||
Follicular lymphoma |
|
|
|
+ | + |
|
+ |
| |||||||||||||||
Mantle cell lymphoma |
|
|
Abdominal distention |
|
+ |
|
|
↓ | Nl to ↓ |
|
|
Elevated LDH | |||||||||||
Diffuse large B cell lymphoma |
|
|
|
↓ | ↓ | Nl to ↓ |
|
Centroblastic
Immunoblastic
Anaplastic
|
|
||||||||||||||
Category | Disease | Etiology | Demography | History | Constitutional symptoms | Rash | Abdominal pain | Diarrhea | V/S | Mass | Hepatosplenomegaly | Other | WBC | Hb | Plt | PBS | PT/PTT | Immunochemistry | Histopathology | Other lab findings | Gold standard | Associated findings | |
Burkitt lymphoma |
|
|
|
|
|||||||||||||||||||
B cell chronic lymphocytic leukemia/small lymphocytic lymphoma |
|
||||||||||||||||||||||
Marginal zone lymphoma | Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type |
|
|||||||||||||||||||||
Splenic marginal zone lymphoma |
|
|
|||||||||||||||||||||
Nodal marginal zone B-cell lymphoma |
|
+ |
|
|
|
| |||||||||||||||||
Lymphoplasmacytic lymphoma (Waldenstrom’s macroglobulinemia) |
|
||||||||||||||||||||||
Hairy cell leukemia |
|
|
|
||||||||||||||||||||
Precursor T-cell lymphoblastic leukemia/lymphoma |
|
||||||||||||||||||||||
Adult T cell leukemia/lymphoma | |||||||||||||||||||||||
T cell lymphoma | Anaplastic large cell lymphoma | ||||||||||||||||||||||
Cutaneous T-cell lymphoma | Mycosis fungoides / Sézary syndrome |
|
|
|
|||||||||||||||||||
Peripheral T-cell lymphoma | Subcutaneous panniculitis-like T-cell lymphoma | ||||||||||||||||||||||
Hepatosplenic gamma-delta T-cell lymphoma | |||||||||||||||||||||||
Enteropathy-type intestinal T-cell lymphoma | |||||||||||||||||||||||
Extranodal T-cell lymphoma, nasal type | |||||||||||||||||||||||
Angioimmunoblastic T-cell lymphoma | |||||||||||||||||||||||
Peripheral T-cell lymphoma, unspecified |